<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39459854</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>26</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1999-4915</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>25</Day></PubDate></JournalIssue><Title>Viruses</Title><ISOAbbreviation>Viruses</ISOAbbreviation></Journal><ArticleTitle>Pediatric Respiratory Hospitalizations in the Pre-COVID-19 Era: The Contribution of Viral Pathogens and Comorbidities to Clinical Outcomes, Valencia, Spain.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1519</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/v16101519</ELocationID><Abstract><AbstractText>Viral respiratory diseases place a heavy burden on the healthcare system, with children making up a significant portion of related hospitalizations. While comorbidities increase the risk of complications and poor outcomes, many hospitalized children lack clear risk factors. As new vaccines for respiratory viral diseases emerge, this study examined pediatric respiratory hospitalizations, focusing on viral etiology, complication rates, and the impact of comorbidities to guide future policy. Data were analyzed from eight pre-COVID influenza seasons (2011/2012-2018/2019) involving patients under 18 years hospitalized with respiratory complaints across 4-10 hospitals in Valencia, Spain. Respiratory specimens were tested for eight viral targets using multiplex real-time reverse-transcription polymerase chain reaction. Demographics, clinical outcomes, discharge diagnoses, and laboratory results were examined. Among the hospitalized children, 26% had at least one comorbidity. These children had higher rates of pneumonia, asthma exacerbation, and pneumothorax, and were twice as likely to require ICU admission, though mechanical ventilation and length of stay were similar to those without comorbidities. Respiratory syncytial virus (RSV) was the most common virus detected (23.1%), followed by rhinovirus/enterovirus (9.5%) and influenza (7.2%). Viral codetection decreased with age, occurring in 4.6% of cases. Comorbidities increase the risk of complications in pediatric respiratory illnesses, however, healthcare utilization is driven largely by otherwise healthy children. Pediatric viral vaccines could reduce this burden and should be further evaluated.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bosch Castells</LastName><ForeName>Valérie</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>New Products and Innovation Medical Franchise, Sanofi Vaccines, 69007 Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mira-Iglesias</LastName><ForeName>Ainara</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-6371-8229</Identifier><AffiliationInfo><Affiliation>Área de Investigación en Vacunas, Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO-Public Health), 46020 Valencia, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Consorcio de Investigación Biomédica de Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, 28029 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>López-Labrador</LastName><ForeName>Francisco Xavier</ForeName><Initials>FX</Initials><Identifier Source="ORCID">0000-0002-9403-8258</Identifier><AffiliationInfo><Affiliation>Consorcio de Investigación Biomédica de Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, 28029 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Área de Genómica y Salud, Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO-Public Health), 46020 Valencia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mengual-Chuliá</LastName><ForeName>Beatriz</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-7605-8175</Identifier><AffiliationInfo><Affiliation>Consorcio de Investigación Biomédica de Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, 28029 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Área de Genómica y Salud, Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO-Public Health), 46020 Valencia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carballido-Fernández</LastName><ForeName>Mario</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-7640-1316</Identifier><AffiliationInfo><Affiliation>Hospital General Universitario de Castellón, 12004 Castellón, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Departamento de Medicina, Universidad CEU Cardenal Herrera, 12004 Castellón, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tortajada-Girbés</LastName><ForeName>Miguel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Hospital Universitario Doctor Peset, 46017 Valencia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mollar-Maseres</LastName><ForeName>Joan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Hospital Universitario y Politécnico La Fe, 46020 Valencia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Puig-Barberà</LastName><ForeName>Joan</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-5783-0409</Identifier><AffiliationInfo><Affiliation>Área de Investigación en Vacunas, Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO-Public Health), 46020 Valencia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Díez-Domingo</LastName><ForeName>Javier</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Área de Investigación en Vacunas, Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO-Public Health), 46020 Valencia, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Consorcio de Investigación Biomédica de Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, 28029 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chaves</LastName><ForeName>Sandra S</ForeName><Initials>SS</Initials><Identifier Source="ORCID">0000-0002-9453-7057</Identifier><AffiliationInfo><Affiliation>New Products and Innovation Medical Franchise, Sanofi Vaccines, 69007 Lyon, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>UNK</GrantID><Agency>Sanofi (France)</Agency><Country /></Grant><Grant><GrantID>UNK</GrantID><Agency>Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana</Agency><Country /></Grant><Grant><GrantID>UNK</GrantID><Agency>Consorcio de investigacion biomedica de Epidemiologia y Salud Publica (CIBERESP)</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Viruses</MedlineTA><NlmUniqueID>101509722</NlmUniqueID><ISSNLinking>1999-4915</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013030" MajorTopicYN="N" Type="Geographic">Spain</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="Y">Hospitalization</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="Y">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012141" MajorTopicYN="Y">Respiratory Tract Infections</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007231" MajorTopicYN="N">Infant, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018357" MajorTopicYN="N">Respiratory Syncytial Virus Infections</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012229" MajorTopicYN="N">Rhinovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">children</Keyword><Keyword MajorTopicYN="N">comorbidities</Keyword><Keyword MajorTopicYN="N">complications</Keyword><Keyword MajorTopicYN="N">hospitalizations</Keyword><Keyword MajorTopicYN="N">respiratory viruses</Keyword><Keyword MajorTopicYN="N">severity</Keyword><Keyword MajorTopicYN="N">viral codetection</Keyword></KeywordList><CoiStatement>V.B.C. and S.S.C. are employees of Sanofi and may hold shares and/or stock options in the company. A.M.-I. has received fees for conferences/experts’ meetings from Sanofi, and for educational events from Merck Sharp &amp; Dohme (MSD). J.D.-D. has attended several congresses whose registration, travel, and accommodation costs were covered by MSD, GlaxoSmithKline (GSK), and Sanofi. J.D.-D. and his institution received research grants from Sanofi and GSK related to respiratory syncytial virus preventive strategies. J.D.-D. has acted as an advisor for these immunization strategies for Sanofi. F.X.L.-L., B.M.-C., M.C.-F., M.T.-G., J.M.-M. and J.P.-B. declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>1</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39459854</ArticleId><ArticleId IdType="pmc">PMC11512402</ArticleId><ArticleId IdType="doi">10.3390/v16101519</ArticleId><ArticleId IdType="pii">v16101519</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Collaborators GLRI Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory tract infections in 195 countries: A systematic analysis for the Global Burden of Disease Study 2015. Lancet Infect. Dis. 2017;17:1133–1161. doi: 10.1016/S1473-3099(17)30396-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(17)30396-1</ArticleId><ArticleId IdType="pmc">PMC5666185</ArticleId><ArticleId IdType="pubmed">28843578</ArticleId></ArticleIdList></Reference><Reference><Citation>Jain S., Williams D.J., Arnold S.R., Ampofo K., Bramley A.M., Reed C., Stockmann C., Anderson E.J., Grijalva C.G., Self W.H., et al. Community-acquired pneumonia requiring hospitalization among U.S. children. N. Engl. J. Med. 2015;372:835–845. doi: 10.1056/NEJMoa1405870.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1405870</ArticleId><ArticleId IdType="pmc">PMC4697461</ArticleId><ArticleId IdType="pubmed">25714161</ArticleId></ArticleIdList></Reference><Reference><Citation>Derqui N., Nealon J., Mira-Iglesias A., Díez-Domingo J., Mahé C., Chaves S.S. Predictors of influenza severity among hospitalized adults with laboratory confirmed influenza: Analysis of nine influenza seasons from the Valencia region, Spain. Influenza Other Respir. Viruses. 2022;16:862–872. doi: 10.1111/irv.12985.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/irv.12985</ArticleId><ArticleId IdType="pmc">PMC9343335</ArticleId><ArticleId IdType="pubmed">35411561</ArticleId></ArticleIdList></Reference><Reference><Citation>Simon T.D., Mahant S., Cohen E. Pediatric Hospital Medicine and Children with Medical Complexity: Past, Present, and Future. Curr. Probl. Pediatr. Adolesc. Health Care. 2012;42:113–119. doi: 10.1016/j.cppeds.2012.01.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cppeds.2012.01.002</ArticleId><ArticleId IdType="pmc">PMC3359150</ArticleId><ArticleId IdType="pubmed">22483081</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren R. Flu-related hospitalization in children. LDI Issue Brief. 2006;12:1–4.</Citation><ArticleIdList><ArticleId IdType="pubmed">17373097</ArticleId></ArticleIdList></Reference><Reference><Citation>American Academy of Pediatrics Committee on Infectious Diseases. American Academy of Pediatrics Bronchiolitis Guidelines Committee Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics. 2014;134:e620–e638. doi: 10.1542/peds.2014-1666.</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.2014-1666</ArticleId><ArticleId IdType="pubmed">25070304</ArticleId></ArticleIdList></Reference><Reference><Citation>Gov.UK.  [(accessed on 28 March 2022)]; Available online:  https://www.gov.uk/government/publications/covid-19-vaccination-resources-for-children-aged-5-to-11-years.</Citation></Reference><Reference><Citation>Rha B., Curns A.T., Lively J.Y., Campbell A.P., Englund J.A., Boom J.A., Azimi P.H., Weinberg G.A., Staat M.A., Selvarangan R., et al. Respiratory Syncytial Virus-Associated Hospitalizations Among Young Children: 2015–2016. Pediatrics. 2020;146:e20193611. doi: 10.1542/peds.2019-3611.</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.2019-3611</ArticleId><ArticleId IdType="pubmed">32546583</ArticleId></ArticleIdList></Reference><Reference><Citation>Arriola C.S., Kim L., Langley G., Anderson E.J., Openo K., Martin A.M., Lynfield R., Bye E., Como-Sabetti K., Reingold A., et al. Estimated Burden of Community-Onset Respiratory Syncytial Virus–Associated Hospitalizations among Children Aged &lt;2 Years in the United States, 2014–2015. J. Pediatr. Infect. Dis. Soc. 2020;9:587–595. doi: 10.1093/jpids/piz087.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jpids/piz087</ArticleId><ArticleId IdType="pmc">PMC7107566</ArticleId><ArticleId IdType="pubmed">31868913</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall C.B., Weinberg G.A., Blumkin A.K., Edwards K.M., Staat M.A., Schultz A.F., Poehling K.A., Szilagyi P.G., Griffin M.R., Williams J.V., et al. Respiratory Syncytial Virus–Associated Hospitalizations Among Children Less Than 24 Months of Age. Pediatrics. 2013;132:e341–e348. doi: 10.1542/peds.2013-0303.</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.2013-0303</ArticleId><ArticleId IdType="pubmed">23878043</ArticleId></ArticleIdList></Reference><Reference><Citation>Hauge S.H., Bakken I.J., de Blasio B.F., Håberg S.E. Risk conditions in children hospitalized with influenza in Norway, 2017–2019. BMC Infect. Dis. 2020;20:769. doi: 10.1186/s12879-020-05486-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-020-05486-6</ArticleId><ArticleId IdType="pmc">PMC7569759</ArticleId><ArticleId IdType="pubmed">33076855</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsankov B.K., Allaire J.M., Irvine M.A., Lopez A.A., Sauvé L.J., Vallance B.A., Jacobson K. Severe COVID-19 Infection and Pediatric Comorbidities: A Systematic Review and Meta-Analysis. Int. J. Infect. Dis. 2021;103:246–256. doi: 10.1016/j.ijid.2020.11.163.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2020.11.163</ArticleId><ArticleId IdType="pmc">PMC7679116</ArticleId><ArticleId IdType="pubmed">33227520</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrar D.S., Drouin O., Hepburn C.M., Baerg K., Chan K., Cyr C., Donner E.J., Embree J.E., Farrell C., Forgie S., et al. Risk factors for severe COVID-19 in hospitalized children in Canada: A national prospective study from March 2020–May 2021. Lancet Reg. Health Am. 2022;15:100337. doi: 10.1016/j.lana.2022.100337.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lana.2022.100337</ArticleId><ArticleId IdType="pmc">PMC9342862</ArticleId><ArticleId IdType="pubmed">35936225</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuzil K.M., Mellen B.G., Wright P.F., Mitchel E.F.J., Griffin M.R. The Effect of Influenza on Hospitalizations, Outpatient Visits, and Courses of Antibiotics in Children. N. Engl. J. Med. 2000;342:225–231. doi: 10.1056/NEJM200001273420401.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM200001273420401</ArticleId><ArticleId IdType="pubmed">10648763</ArticleId></ArticleIdList></Reference><Reference><Citation>Demont C., Petrica N., Bardoulat I., Duret S., Watier L., Chosidow A., Lorrot M., Kieffer A., Lemaitre M. Economic and disease burden of RSV-associated hospitalizations in young children in France, from 2010 through 2018. BMC Infect. Dis. 2021;21:730. doi: 10.1186/s12879-021-06399-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-021-06399-8</ArticleId><ArticleId IdType="pmc">PMC8327424</ArticleId><ArticleId IdType="pubmed">34340679</ArticleId></ArticleIdList></Reference><Reference><Citation>Zipkin M. New Vaccine Approaches Present New Possibilities, But New Challenges. Nat. Biopharma Deal. Mak. News Feature. 2021 doi: 10.1038/d43747-021-00079-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d43747-021-00079-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Focosi D. From Co-Administration to Co-Formulation: The Race for New Vaccines against COVID-19 and Other Respiratory Viruses. Vaccines. 2023;11:109. doi: 10.3390/vaccines11010109.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines11010109</ArticleId><ArticleId IdType="pmc">PMC9860680</ArticleId><ArticleId IdType="pubmed">36679954</ArticleId></ArticleIdList></Reference><Reference><Citation>Belshe R.B., Newman F.K., Anderson E.L., Wright P.F., Karron R.A., Tollefson S., Henderson F.W., Meissner H.C., Madhi S., Roberton D., et al. Evaluation of Combined Live, Attenuated Respiratory Syncytial Virus and Parainfluenza 3 Virus Vaccines in Infants and Young Children. J. Infect. Dis. 2004;190:2096–2103. doi: 10.1086/425981.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/425981</ArticleId><ArticleId IdType="pubmed">15551207</ArticleId></ArticleIdList></Reference><Reference><Citation>Puig-Barberà J., Tormos A., Sominina A., Burtseva E., Launay O., Ciblak M.A., Natividad-Sancho A., Buigues-Vila A., Martínez-Úbeda S., Mahé C. First-year results of the Global Influenza Hospital Surveillance Network: 2012–2013 Northern hemisphere influenza season. BMC Public Health. 2014;14:564. doi: 10.1186/1471-2458-14-564.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2458-14-564</ArticleId><ArticleId IdType="pmc">PMC4057821</ArticleId><ArticleId IdType="pubmed">24903737</ArticleId></ArticleIdList></Reference><Reference><Citation>Puig-Barberà J., Tormos A., Trushakova S., Sominina A., Pisareva M., Ciblak M.A., Badur S., Yu H., Cowling B.J., Burtseva E., et al. The Global Influenza Hospital Surveillance Network (GIHSN): A new platform to describe the epidemiology of severe influenza. Influ. Other Respir. Viruses. 2015;9:277–286. doi: 10.1111/irv.12335.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/irv.12335</ArticleId><ArticleId IdType="pmc">PMC4605407</ArticleId><ArticleId IdType="pubmed">26198771</ArticleId></ArticleIdList></Reference><Reference><Citation>Mira-Iglesias A., López-Labrador F.X., García-Rubio J., Mengual-Chuliá B., Tortajada-Girbés M., Mollar-Maseres J., Carballido-Fernández M., Schwarz-Chavarri G., Puig-Barberà J., Díez-Domingo J. Influenza Vaccine Effectiveness and Waning Effect in Hospitalized Older Adults. Valencia Region, Spain, 2018/2019 Season. Int. J. Environ. Res. Public Health. 2021;18:1129. doi: 10.3390/ijerph18031129.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph18031129</ArticleId><ArticleId IdType="pmc">PMC7908304</ArticleId><ArticleId IdType="pubmed">33514058</ArticleId></ArticleIdList></Reference><Reference><Citation>Mira-Iglesias A., López-Labrador F.X., Baselga-Moreno V., Tortajada-Girbés M., Mollar-Maseres J., Carballido-Fernández M., Schwarz-Chavarri G., Puig-Barberà J., Díez-Domingo J. Influenza vaccine effectiveness against laboratory-confirmed influenza in hospitalised adults aged 60 years or older, Valencia Region, Spain, 2017/18 influenza season. Euro Surveill. 2019;24 doi: 10.2807/1560-7917.ES.2019.24.31.1800461.</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2019.24.31.1800461</ArticleId><ArticleId IdType="pmc">PMC6685101</ArticleId><ArticleId IdType="pubmed">31387672</ArticleId></ArticleIdList></Reference><Reference><Citation>Mira-Iglesias A., López-Labrador F.X., Guglieri-López B., Tortajada-Girbés M., Baselga-Moreno V., Cano L., Mollar-Maseres J., Carballido-Fernández M., Schwarz-Chavarri G., Díez-Domingo J., et al. Influenza vaccine effectiveness in preventing hospitalisa-tion of individuals 60 years of age and over with laboratory-confirmed influenza, Valencia Region, Spain, influenza season 2016/17. Euro Surveill. 2018;23 doi: 10.2807/1560-7917.ES.2018.23.8.17-00318.</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2018.23.8.17-00318</ArticleId><ArticleId IdType="pmc">PMC5829534</ArticleId><ArticleId IdType="pubmed">29486829</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen P.R., Rybak A., Werner A., Béchet S., Desandes R., Hassid F., André J.M., Gelbert N., Thiebault G., Kochert F., et al. Trends in pediatric ambulatory community acquired infections before and during COVID-19 pandemic: A prospective multicentric sur-veillance study in France. Lancet Reg. Health Eur. 2022;22:100497. doi: 10.1016/j.lanepe.2022.100497.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanepe.2022.100497</ArticleId><ArticleId IdType="pmc">PMC9398201</ArticleId><ArticleId IdType="pubmed">36034052</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker R.E., Park S.W., Yang W., Vecchi G.A., Metcalf C.J.E., Grenfell B.T. The impact of COVID-19 nonpharmaceutical interventions on the future dynamics of endemic infections. Proc. Natl. Acad. Sci. USA. 2020;117:30547–30553. doi: 10.1073/pnas.2013182117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2013182117</ArticleId><ArticleId IdType="pmc">PMC7720203</ArticleId><ArticleId IdType="pubmed">33168723</ArticleId></ArticleIdList></Reference><Reference><Citation>European Centre for Disease Prevention and Control  . Commission Implementing Decision (EU) 2018/945 of 22 June 2018 on the Communicable Diseases and Related Health Issues to Be Covered by Epidemiological Surveillance As Well As Relevant Case Definitions. Volume 1–74. European Centre for Disease Prevention and Control; Solna, Sweden: 2018.  [(accessed on 1 July 2024)].  Available online:  https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32018D0945.</Citation></Reference><Reference><Citation>Thompson M.G., Levine M.Z., Bino S., Hunt D.R., Al-Sanouri T.M., Simões E.A.F., Porter R.M., Biggs H.M., Gresh L., Simaku A., et al. Underdetection of laboratory-confirmed influenza-associated hospital admissions among infants: A multicentre, prospective study. Lancet Child Adolesc. Health. 2019;3:781–794. doi: 10.1016/S2352-4642(19)30246-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2352-4642(19)30246-9</ArticleId><ArticleId IdType="pmc">PMC7029431</ArticleId><ArticleId IdType="pubmed">31492594</ArticleId></ArticleIdList></Reference><Reference><Citation>Norman D.A., Cheng A.C., Macartney K.K., Moore H.C., Danchin M., Seale H., McRae J., Clark J.E., Marshall H.S., Buttery J., et al. Influenza hospitalizations in Australian children 2010-2019: The impact of medical comorbidities on outcomes, vaccine coverage, and effectiveness. Influenza Other Respir Viruses. 2022;16:316–327. doi: 10.1111/irv.12939.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/irv.12939</ArticleId><ArticleId IdType="pmc">PMC8818821</ArticleId><ArticleId IdType="pubmed">34787369</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarna M., Lambert S.B., Sloots T.P., Whiley D.M., Alsaleh A., Mhango L., Bialasiewicz S., Wang D., Nissen M.D., Grimwood K., et al. Viruses causing lower respiratory symptoms in young children: Findings from the ORChID birth cohort. Thorax. 2017;73:969–979. doi: 10.1136/thoraxjnl-2017-210233.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/thoraxjnl-2017-210233</ArticleId><ArticleId IdType="pmc">PMC6166599</ArticleId><ArticleId IdType="pubmed">29247051</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Corre N., Pérez R., Vizcaya C., Martínez-Valdebenito C., López T., Monge M., Alarcón R., Moller F., Martínez M.T., Massardo J.M., et al. Relevance of codetection of respiratory viruses in the severity of acute respiratory infection in hospitalized children. Andes Pediatr. 2021;92:349–357. doi: 10.32641/andespediatr.v92i3.1756.</Citation><ArticleIdList><ArticleId IdType="doi">10.32641/andespediatr.v92i3.1756</ArticleId><ArticleId IdType="pubmed">34479240</ArticleId></ArticleIdList></Reference><Reference><Citation>Agathis N.T., Patel K., Milucky J., Taylor C.A., Whitaker M., Pham H., Anglin O., Chai S.J., Alden N.B., Meek J., et al. Codetections of Other Respiratory Viruses Among Children Hospitalized with COVID-19. Pediatrics. 2023;151 doi: 10.1542/peds.2022-059037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.2022-059037</ArticleId><ArticleId IdType="pubmed">36995184</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin G.-L., Drysdale S., Snape M., O’Connor D., Brown A., MacIntyre-Cockett G., Mellado-Gomez E., de Cesare M., Ansari A., Bonsall D., et al. Association between disease severity and co-detection of respiratory pathogens in infants with RSV infection. medRxiv. 2023 doi: 10.1101/2023.02.12.23285726.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2023.02.12.23285726</ArticleId></ArticleIdList></Reference><Reference><Citation>Samson L., Cooke C., MacDonald N. Analysis of antibiotic use and misuse in children hospitalized with RSV infection. Paediatr. Child Health. 1999;4:195–199. doi: 10.1203/00006450-199604001-00675.</Citation><ArticleIdList><ArticleId IdType="doi">10.1203/00006450-199604001-00675</ArticleId><ArticleId IdType="pmc">PMC2828193</ArticleId><ArticleId IdType="pubmed">20212965</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Houten C.B., Cohen A., Engelhard D., Hays J.P., Karlsson R., Moore E., Fernández D., Kreisberg R., Collins L.V., de Waal W., et al. Antibiotic misuse in respiratory tract infections in children and adults—A prospective, multicentre study (TAILORED Treatment) Eur. J. Clin. Microbiol. Infect. Dis. 2019;38:505–514. doi: 10.1007/s10096-018-03454-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10096-018-03454-2</ArticleId><ArticleId IdType="pmc">PMC6394715</ArticleId><ArticleId IdType="pubmed">30707378</ArticleId></ArticleIdList></Reference><Reference><Citation>Han S.B., Shin J.A., Kim S.K., Lee J.W., Lee D.-G., Chung N.-G., Cho B., Jeong D.C., Kang J.H. Respiratory viral infections in children and adolescents with hematological malignancies. Mediterr. J. Hematol. Infect. Dis. 2019;11:e2019006. doi: 10.4084/mjhid.2019.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.4084/mjhid.2019.006</ArticleId><ArticleId IdType="pmc">PMC6328038</ArticleId><ArticleId IdType="pubmed">30671212</ArticleId></ArticleIdList></Reference><Reference><Citation>Britton P.N., Jones C.A., Macartney K., Cheng A.C. Parechovirus: An important emerging infection in young infants. Med. J. Aust. 2018;208:365–369. doi: 10.5694/mja18.00149.</Citation><ArticleIdList><ArticleId IdType="doi">10.5694/mja18.00149</ArticleId><ArticleId IdType="pubmed">29716506</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah M.M., Perez A., Lively J.Y., Avadhanula V., Boom J.A., Chappell J., Englund J.A., Fregoe W., Halasa N.B., Harrison C.J., et al. Enterovirus D68-Associated Acute Respiratory Illness—New Vaccine Surveillance Network, United States, July–November 2018–2020. MMWR Morb. Mortal. Wkly. Rep. 2021;70:1623–1628. doi: 10.15585/mmwr.mm7047a1.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7047a1</ArticleId><ArticleId IdType="pmc">PMC8612514</ArticleId><ArticleId IdType="pubmed">34818320</ArticleId></ArticleIdList></Reference><Reference><Citation>Monto A.S. The seasonality of rhinovirus infections and its implications for clinical recognition. Clin. Ther. 2002;24:1987–1997. doi: 10.1016/S0149-2918(02)80093-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0149-2918(02)80093-5</ArticleId><ArticleId IdType="pmc">PMC7133757</ArticleId><ArticleId IdType="pubmed">12581541</ArticleId></ArticleIdList></Reference><Reference><Citation>Pons-Salort M., Oberste M.S., Pallansch M.A., Abedi G.R., Takahashi S., Grenfell B.T., Grassly N.C. The seasonality of nonpolio enteroviruses in the United States: Patterns and drivers. Proc. Natl. Acad. Sci. USA. 2018;115:3078–3083. doi: 10.1073/pnas.1721159115.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1721159115</ArticleId><ArticleId IdType="pmc">PMC5866597</ArticleId><ArticleId IdType="pubmed">29507246</ArticleId></ArticleIdList></Reference><Reference><Citation>European Centre for Disease Prevention and Control. World Health Organization  Operational Considerations for Respiratory Virus Surveillance in Europe, 18 July 2022. WHO/EURO:2022-5841-45606-65427. 2022.  [(accessed on 1 July 2024)].  Available online:  https://www.who.int/europe/publications/i/item/WHO-EURO-2022-5841-45606-65427.</Citation></Reference><Reference><Citation>Fiore A.E., Uyeki T.M., Broder K., Finelli L., Euler G.L., Singleton J.A., Iskander J.K., Wortley P.M., Shay D.K., Bresee J.S., et al. Prevention and control of influenza with vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm. Rep. 2010;59:1–62.</Citation><ArticleIdList><ArticleId IdType="pubmed">20689501</ArticleId></ArticleIdList></Reference><Reference><Citation>Mak T.K., Mangtani P., Leese J., Watson J.M., Pfeifer D. Influenza vaccination in pregnancy: Current evidence and selected national policies. Lancet Infect. Dis. 2008;8:44–52. doi: 10.1016/S1473-3099(07)70311-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(07)70311-0</ArticleId><ArticleId IdType="pubmed">18156088</ArticleId></ArticleIdList></Reference><Reference><Citation>Morales K.F., Brown D.W., Dumolard L., Steulet C., Vilajeliu A., Alvarez A.M.R., Moen A., Friede M., Lambach P. Seasonal influenza vaccination policies in the 194 WHO Member States: The evolution of global influenza pandemic preparedness and the challenge of sustaining equitable vaccine access. Vaccine X. 2021;8:100097. doi: 10.1016/j.jvacx.2021.100097.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jvacx.2021.100097</ArticleId><ArticleId IdType="pmc">PMC8143996</ArticleId><ArticleId IdType="pubmed">34041476</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen S.A., Chui K.K., Naumova E.N. Influenza Vaccination in Young Children Reduces Influenza-Associated Hospitalizations in Older Adults, 2002–2006. J. Am. Geriatr. Soc. 2011;59:327–332. doi: 10.1111/j.1532-5415.2010.03271.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1532-5415.2010.03271.x</ArticleId><ArticleId IdType="pmc">PMC3111961</ArticleId><ArticleId IdType="pubmed">21275932</ArticleId></ArticleIdList></Reference><Reference><Citation>Dbaibo G., Amanullah A., Claeys C., Izu A., Jain V.K., Kosalaraksa P., Rivera L., Soni J., Yanni E., Zaman K., et al. Quadrivalent Influenza Vaccine Prevents Illness and Reduces Healthcare Utilization Across Diverse Geographic Regions During Five Influenza Seasons: A Randomized Clinical Trial. Pediatr. Infect Dis. J. 2020;39:e1–e10. doi: 10.1097/INF.0000000000002504.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/INF.0000000000002504</ArticleId><ArticleId IdType="pmc">PMC7004464</ArticleId><ArticleId IdType="pubmed">31725115</ArticleId></ArticleIdList></Reference><Reference><Citation>King J.C.J., Stoddard J.J., Gaglani M.J., Moore K.A., Magder L., McClure E., Rubin J.D., Englund J.A., Neuzil K. Effectiveness of School-Based Influenza Vaccination. N. Engl. J. Med. 2006;355:2523–2532. doi: 10.1056/NEJMoa055414.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa055414</ArticleId><ArticleId IdType="pubmed">17167135</ArticleId></ArticleIdList></Reference><Reference><Citation>Gantenberg J.R., van Aalst R., Zimmerman N., Limone B., Chaves S.S., La Via W.V., Nelson C.B., Rizzo C., Savitz D.A., Zullo A.R. Medically Attended Illness due to Respiratory Syncytial Virus Infection Among Infants Born in the United States Between 2016 and 2020. J. Infect. Dis. 2022;226((Suppl. S2)):S164–S174. doi: 10.1093/infdis/jiac185.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiac185</ArticleId><ArticleId IdType="pmc">PMC9377038</ArticleId><ArticleId IdType="pubmed">35968869</ArticleId></ArticleIdList></Reference><Reference><Citation>Wildenbeest J.G., Billard M.-N., Zuurbier R.P., Korsten K., Langedijk A.C., van de Ven P.M., Snape M.D., Drysdale S.B., Pollard A.J., Robinson H., et al. The burden of respiratory syncytial virus in healthy term-born infants in Europe: A prospective birth cohort study. Lancet Respir. Med. 2022;11:341–353. doi: 10.1016/S2213-2600(22)00414-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(22)00414-3</ArticleId><ArticleId IdType="pmc">PMC9764871</ArticleId><ArticleId IdType="pubmed">36372082</ArticleId></ArticleIdList></Reference><Reference><Citation>Domachowske J.B., Anderson E.J., Goldstein M. The Future of Respiratory Syncytial Virus Disease Prevention and Treatment. Infect. Dis. Ther. 2021;10((Suppl. S1)):47–60. doi: 10.1007/s40121-020-00383-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40121-020-00383-6</ArticleId><ArticleId IdType="pmc">PMC7926075</ArticleId><ArticleId IdType="pubmed">33656652</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazur N.I., Terstappen J., Baral R., Bardají A., Beutels P., Buchholz U.J., Cohen C., Crowe J.E., Cutland C.L., Eckert L., et al. Respiratory syncytial virus prevention within reach: The vaccine and monoclonal antibody landscape. Lancet Infect. Dis. 2023 doi: 10.1016/S1473-3099(22)00291-2. in press .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(22)00291-2</ArticleId><ArticleId IdType="pmc">PMC9896921</ArticleId><ArticleId IdType="pubmed">35952703</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammitt L.L., Dagan R., Yuan Y., Cots M.B., Bosheva M., Madhi S.A., Muller W.J., Zar H.J., Brooks D., Grenham A., et al. Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants. N. Engl. J. Med. 2022;386:837–846. doi: 10.1056/NEJMoa2110275.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2110275</ArticleId><ArticleId IdType="pubmed">35235726</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffin M.P., Yuan Y., Takas T., Domachowske J.B., Madhi S.A., Manzoni P., Simões E.A.F., Esser M.T., Khan A.A., Dubovsky F., et al. Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants. N. Engl. J. Med. 2020;383:415–425. doi: 10.1056/NEJMoa1913556.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1913556</ArticleId><ArticleId IdType="pubmed">32726528</ArticleId></ArticleIdList></Reference><Reference><Citation>Simões E.A.F., Madhi S.A., Muller W.J., Atanasova V., Bosheva M., Cabañas F., Cots M.B., Domachowske J.B., Garcia-Garcia M.L., Grantina I., et al. Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: A pooled analysis of randomised controlled trials. Lancet Child Adolesc. Health. 2023;7:180–189. doi: 10.1016/s2352-4642(22)00321-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s2352-4642(22)00321-2</ArticleId><ArticleId IdType="pmc">PMC9940918</ArticleId><ArticleId IdType="pubmed">36634694</ArticleId></ArticleIdList></Reference><Reference><Citation>Aliprantis A.O., Wolford D., Caro L., Maas B.M., Ma H., Montgomery D.L., Sterling L.M., Hunt A., Cox K.S., Vora K.A., et al. A Phase 1 Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety, Tolerability, and Pharmacokinetics of a Respiratory Syncytial Virus Neutralizing Monoclonal Antibody MK-1654 in Healthy Adults. Clin. Pharmacol. Drug Dev. 2021;10:556–566. doi: 10.1002/cpdd.883.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cpdd.883</ArticleId><ArticleId IdType="pubmed">33125189</ArticleId></ArticleIdList></Reference><Reference><Citation>Sah P., Vilches T.N., Pandey A., Schneider E.C., Moghadas S.M., Galvani A.P. Estimating the impact of vaccination on reducing COVID-19 burden in the United States: December 2020 to March 2022. J. Glob. Health. 2022;12:03062. doi: 10.7189/jogh.12.03062.</Citation><ArticleIdList><ArticleId IdType="doi">10.7189/jogh.12.03062</ArticleId><ArticleId IdType="pmc">PMC9441009</ArticleId><ArticleId IdType="pubmed">36056814</ArticleId></ArticleIdList></Reference><Reference><Citation>Dawood F.S., Chaves S.S., Pérez A., Reingold A., Meek J., Farley M.M., Ryan P., Lynfield R., Morin C., Baumbach J., et al. Emerging Infections Program Network. Complications and Associated Bacterial Coinfections Among Children Hospitalized with Seasonal or Pandemic Influenza, United States, 2003–2010. J. Infect. Dis. 2014;209:686–694. doi: 10.1093/infdis/jit473.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jit473</ArticleId><ArticleId IdType="pubmed">23986545</ArticleId></ArticleIdList></Reference><Reference><Citation>Reed C., Chaves S.S., Perez A., D’Mello T., Kirley P.D., Aragon D., Meek J.I., Farley M.M., Ryan P., Lynfield R., et al. Complications Among Adults Hospitalized with Influenza: A Comparison of Seasonal Influenza and the 2009 H1N1 Pandemic. Clin. Infect. Dis. 2014;59:166–174. doi: 10.1093/cid/ciu285.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciu285</ArticleId><ArticleId IdType="pmc">PMC7314251</ArticleId><ArticleId IdType="pubmed">24785230</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>